- Conditions
- Zellweger Spectrum Disorder
- Interventions
- Not listed
- Lead sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- Other
- Eligibility
- Not listed
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- Rochester, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 289–312
of 1,616
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Retinopathy of Prematurity
- Interventions
- Ranibizumab, Laser therapy
- Drug · Procedure
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- Not listed
- Enrollment
- 224 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 12
- States / cities
- Loma Linda, California • Sacramento, California • Aurora, Colorado + 9 more
- Conditions
- Macular Degeneration
- Interventions
- Omega-3 fatty acid
- Dietary Supplement
- Lead sponsor
- Wills Eye
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 4
- States / cities
- Cherry Hill, New Jersey • Bethlehem, Pennsylvania • Huntingdon Valley, Pennsylvania + 1 more
- Conditions
- Retinal Detachment
- Interventions
- Retinal Detachment repair
- Procedure
- Lead sponsor
- Wills Eye
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Glaucoma, Ocular Hypertension
- Interventions
- Glaucoma screening using an AI-algorithm and screening for diabetic retinopathy, cataract, and visual acuity impairment.
- Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Retinitis Pigmentosa, Retinal Dystrophy
- Interventions
- Observational
- Other
- Lead sponsor
- Nanoscope Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Miami, Florida + 4 more
- Conditions
- Diabetic Retinopathy
- Interventions
- Finerenone (BAY94-8862)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- Not listed
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 10
- States / cities
- Chula Vista, California • El Centro, California • Fort Lauderdale, Florida + 7 more
- Conditions
- Diabetic Retinopathy
- Interventions
- Octreotide Acetate in Microspheres 20 mg, Octreotide Acetate in Microspheres, Placebo
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 583 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2005
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Diabetes Complications, Diabetic Retinopathy
- Interventions
- Generation of inducible pluripotent stem cells
- Biological
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 21 Years to 98 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Retinal Detachment, Achilles Tendon, Aneurysm, Dissecting
- Interventions
- Oral Fluoroquinolones (FQ), Other Antibiotics, Febrile Illness Not Treated with Antibiotics Will be Analyzed as an Exposure
- Drug · Other
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- Not listed
- Enrollment
- 117,911 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Titusville, New Jersey
- Conditions
- Choroidal Melanoma
- Interventions
- ranibizumab
- Drug
- Lead sponsor
- Massachusetts Eye and Ear Infirmary
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Retinitis Pigmentosa, Choroideremia, Stargardt Macular Dystrophy, Stargardt Disease, Geographic Atrophy from Age-related Macular Degeneration, X-lined Retinoschisis, Retinal Dystrophies
- Interventions
- Not listed
- Lead sponsor
- Ray Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Irvine, California
- Conditions
- Bronchopulmonary Dysplasia, Chronic Lung Disease of Prematurity, Intraventricular Hemorrhage, Retinopathy of Prematurity (ROP)
- Interventions
- OHB-607
- Drug
- Lead sponsor
- OHB Neonatology Ltd.
- Industry
- Eligibility
- 0 Hours to 24 Hours
- Enrollment
- 295 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 24
- States / cities
- Little Rock, Arkansas • California City, California • Los Angeles, California + 19 more
- Conditions
- Leber Congenital Amaurosis
- Interventions
- Not listed
- Lead sponsor
- MeiraGTx UK II Ltd
- Industry
- Eligibility
- 3 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Diabetic Retinopathy, DR
- Interventions
- Standard of Care, Aflibercept
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- Not listed
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2031
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 17 more
- Conditions
- Retinitis Pigmentosa
- Interventions
- Ophthalmic examinations, Mobility Test
- Other
- Lead sponsor
- SparingVision
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Macular Degeneration, Choroidal Neovascularization
- Interventions
- Ocular Brachytherapy
- Device
- Lead sponsor
- Theragenics Corporation
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 6
- States / cities
- Atlanta, Georgia • Augusta, Georgia • Indianapolis, Indiana + 3 more
- Conditions
- Retinal Diseases, Optic Nerve Diseases
- Interventions
- Duke Biomedical Engineering's Long-working distance OCT
- Device
- Lead sponsor
- Duke University
- Other
- Eligibility
- 6 Months and older
- Enrollment
- 49 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Diabetic Macular Edema
- Interventions
- OXU-001, Semi-automated suprachoroidal illuminated microcatheter, Ozurdex® Ophthalmic Intravitreal Implant
- Drug · Device
- Lead sponsor
- Oxular Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • Clearwater, Florida • Oak Forest, Illinois + 5 more
- Conditions
- Uveitic Macular Edema, Intraocular Inflammation
- Interventions
- Infliximab (intravitreal, 2.0mg/0.05ml)
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Retinitis Pigmentosa, Eye Diseases, Hereditary, Retinal Dystrophies, Retinal Dystrophy Rod, Retinal Dystrophy Rod Progressive
- Interventions
- Not listed
- Lead sponsor
- PYC Therapeutics
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 5
- States / cities
- San Francisco, California • Jacksonville, Florida • Ann Arbor, Michigan + 2 more
- Conditions
- Anterior Uveitis (AU), Birdshot Chorioretinitis, Behcet Disease, Herpes Simplex Virus, Juvenile Idiopathic Arthritis (JIA), Spondyloarthritis (SA), Sarcoidosis, Posterior Vitreous Detachment
- Interventions
- Not listed
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 5 Years to 85 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Eye Diseases, Retinitis Pigmentosa, Diabetic Retinopathy, Macular Degeneration, Traumatic Optic Neuropathy, Optic Atrophy
- Interventions
- cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell exosomes
- Biological
- Lead sponsor
- The Foundation for Orthopaedics and Regenerative Medicine
- Other
- Eligibility
- Not listed
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Naples, Florida
- Conditions
- Diabetic Retinopathy
- Interventions
- PAN-90806 Ophthalmic Solution
- Drug
- Lead sponsor
- PanOptica, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 2
- States / cities
- Harlingen, Texas • McAllen, Texas